Lipoprotein(a) (Lp[a]) and oxidized phospholipids (OxPLs) are associated with severity and outcomes in patients with coronary artery disease (CAD) independent of low-density lipoprotein cholesterol (LDL-C) and other established clinical predictors, according to findings from the CASABLANCA trial.